What changes are lawmakers proposing in the new 340B overhaul bill?

Lawmakers are advancing legislation to revamp the federal 340B drug pricing program, reflecting renewed scrutiny of how discounts are used by hospitals, drugmakers, and contract pharmacies. The effort signals Congress’s concern that the program’s growth may have exceeded its original safety‑net intent, reigniting long‑running disputes over eligibility and revenue distribution.